Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03798639 | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | completed | Phase 1 | 7 | Claire VerschraegenOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02155647 | Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) | completed | Phase 2 | 204 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Mar 13, 2024 | clinicaltrials |
| NCT04834778 | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | completed | Phase 1 | 23 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04421352 | Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients | completed | Phase 1 | 11 | CStone PharmaceuticalsINDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT02592356 | Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer | completed | N/A | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00019006 | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01540045 | Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | completed | — | 40 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03012620 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 334 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03834701 | Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms(RAPNEN) | completed | N/A | 60 | Catholic University of the Sacred HeartOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03639194 | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 132 | AbbVieINDUSTRY | 4 | Feb 9, 2024 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06243965 | Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?(DSR-MTC) | completed | — | 246 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04878016 | A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC | completed | Phase 3 | 498 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03297788 | Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases(ENCEPHALON) | completed | N/A | 56 | Juergen DebusOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04361825 | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects(SUKSES-N4) | completed | Phase 2 | 42 | Se-Hoon LeeOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 24 | Shadia Jalal, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT02318784 | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05422781 | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | completed | Phase 1 | 6 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04229381 | Resiliency Among Older Adults Receiving Lung Cancer Treatment(ROAR-LCT) | completed | N/A | 18 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | completed | Phase 1 | 105 | Syros PharmaceuticalsINDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT01401907 | Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | completed | N/A | 351 | Massachusetts General HospitalOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067594 | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | completed | — | 155 | Austral University, ArgentinaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT00856037 | Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 22 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03216343 | Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer | completed | Phase 1 | 48 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT05026593 | A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 60 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 140 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02267603 | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04452292 | Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma(PRECISION-NEC) | completed | N/A | 2 | Charles KunosOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT01440816 | IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer(MCC) | completed | Phase 2 | 15 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00193531 | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04672928 | A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | completed | Phase 1 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05673798 | Development and Validation of Nomogram Predicting Survival in Chinese SCLC Patients | completed | — | 569 | The Second Hospital of Shandong UniversityOTHER | 0 | Jan 10, 2023 | clinicaltrials |
| NCT05285033 | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC(LURBICLIN) | completed | — | 312 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05671393 | the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma | completed | — | 801 | Fujian Medical UniversityOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03545334 | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study(LIMIT) | completed | N/A | 93 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT03079440 | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2024source: clinicaltrials